Interleukin-1α (IL-1α), IL-1β, IL-1 receptor type I, IL-1 receptor antagonist, and TGF-β1 mRNAs in pediatric astrocytomas, ependymomas, and primitive neuroectodermal tumors

被引:21
|
作者
Ilyin, SE
Gonzalez-Gomez, I
Gilles, FH
Plata-Salaman, CR [1 ]
机构
[1] Univ Delaware, Sch Life & Hlth Sci, Div Mol Biol, Newark, DE 19716 USA
[2] Childrens Hosp, Dept Pathol, Los Angeles, CA 90027 USA
关键词
astrocyte; astrocytomas; brain tumor; cytokine; ependymomas; glia; growth factor; interleukins; nervous system; neuron; posterior fossa; RNase protection; TGF;
D O I
10.1007/BF02870186
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Interleukin-1 alpha (IL-1 alpha), IL-1 beta, interleukin-l receptor type I(IL-1RI, signaling receptor), and IL-1 receptor antagonist (IL-1Ra, endogenous inhibitor) are pivotal components of the IL-1 system. IL-1 and other cytokines induced by IL-1, such as TGF-beta 1, may participate in the growth of various tumor cells. In children, primary nervous system tumors represent the most common solid malignancy. We investigated the levels of IL-1 alpha, IL-1 beta, IL-1RI, IL-1Ra, and TGF-beta 1 mRNAs in pediatric astrocytomas (n = 19), ependymomas (n = 13), and primitive neuroectodermal tumors (n = 22) using sensitive and specific RNase protection assays. The data show a significant distinct cytokine mRNA profile among brain tumor types. Pilocytic, nonpilocytic, and anaplastic astrocytomas have significant increased levels of IL-1 beta, IL-1RI, and TGF-beta 1 mRNAs, but low levels of IL-1Ra mRNA; this may have implications for an IL-1 beta feedback system and IL-1 beta <-> TGF-beta 1 interactions in astrocytomas. Ependymomas show increased levels of IL-1 alpha and IL-1 beta mRNAs associated with low levels of IL-1Ra mRNA; primitive neuroectodermal tumors do not exhibit increased levels of any cytokine component examined. The data also suggest that a dysregulation of the balance between stimulatory and inhibitory cytokines may be involved in the growth and development of brain tumors via autocrine/paracrine mechanisms.
引用
收藏
页码:125 / 137
页数:13
相关论文
共 50 条
  • [31] IL-1 INDUCES RAPID PHOSPHORYLATION OF THE IL-1 RECEPTOR
    GALLIS, B
    PRICKETT, KS
    JACKSON, J
    SLACK, J
    SCHOOLEY, K
    SIMS, JE
    DOWER, SK
    JOURNAL OF IMMUNOLOGY, 1989, 143 (10): : 3235 - 3240
  • [32] Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein
    Hofmeister, R
    Wiegmann, K
    Korherr, C
    Bernardo, K
    Kronke, M
    Falk, W
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (44) : 27730 - 27736
  • [33] Interleukin-1 (IL-1) receptor type I mediates anorexia but not adipsia induced by centrally administered IL-1 beta
    Sonti, G
    Flynn, MC
    PlataSalaman, CR
    PHYSIOLOGY & BEHAVIOR, 1997, 62 (05) : 1179 - 1183
  • [34] Interleukin (IL)-1β regulation of IL-1β and IL-1 receptor antagonist expression in cultured human endometrial stromal cells
    Huang, HY
    Wen, Y
    Kruessel, JS
    Raga, F
    Soong, YK
    Polan, ML
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03): : 1387 - 1393
  • [35] Studies of interleukin-1β and its receptor IL-1 receptor 2 and antagonist IL-1 receptor antagonist in stable chronic obstructive pulmonary disease
    Sapey, E
    Bayley, D
    Griffiths, D
    Newbold, P
    Stockley, RA
    THORAX, 2005, 60 : II85 - II85
  • [36] IL-1 Receptor Antagonist Reduced Chemical-Induced Keratinocyte Apoptosis through Antagonism to IL-1α/IL-1β
    Lee, Hyejin
    Cheong, Kyung Ah
    Kim, Ji-Young
    Kim, Nan-Hyung
    Noh, Minsoo
    Lee, Ai-Young
    BIOMOLECULES & THERAPEUTICS, 2018, 26 (04) : 417 - +
  • [37] Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes
    Luotola, K.
    Pietila, A.
    Zeller, T.
    Moilanen, L.
    Kahonen, M.
    Nieminen, M. S.
    Kesaniemi, Y. A.
    Blankenberg, S.
    Jula, A.
    Perola, M.
    Salomaa, V.
    JOURNAL OF INTERNAL MEDICINE, 2011, 269 (03) : 322 - 332
  • [38] The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness
    Lang, D
    Knop, J
    Wesche, H
    Raffetseder, U
    Kurrle, R
    Boraschi, D
    Martin, MU
    JOURNAL OF IMMUNOLOGY, 1998, 161 (12): : 6871 - 6877
  • [39] SUPPRESSION OF CHRONIC MYELOGENOUS LEUKEMIA COLONY GROWTH BY INTERLEUKIN-1 (IL-1) RECEPTOR ANTAGONIST AND SOLUBLE IL-1 RECEPTORS - A NOVEL APPLICATION FOR INHIBITORS OF IL-1 ACTIVITY
    ESTROV, Z
    KURZROCK, R
    WETZLER, M
    KANTARJIAN, H
    BLAKE, M
    HARRIS, D
    GUTTERMAN, JU
    TALPAZ, M
    BLOOD, 1991, 78 (06) : 1476 - 1484
  • [40] THE EFFECT OF ANTIRHEUMATIC DRUGS ON INTERLEUKIN-1 (IL-1) ACTIVITY AND IL-1 AND IL-1 INHIBITOR PRODUCTION BY HUMAN MONOCYTES
    CHANG, DM
    BAPTISTE, P
    SCHUR, PH
    JOURNAL OF RHEUMATOLOGY, 1990, 17 (09) : 1148 - 1157